



September 03, 2025

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

To,
Listing/ Compliance Department
**National Stock Exchange of
India Limited**
"Exchange Plaza", Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
SYMBOL: AARTIPHARM

Dear Sir/Madam,

Sub: Press Release by the Company.
Ref: Regulation 30 of SEBI (LODR) Regulations,
2015 ('Listing Regulations')

Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release dated September 03, 2025 titled "**Aarti Pharmalabs Limited inaugurates its new state-of- art manufacturing facility at Atali, Gujarat to expand its production capacity**".

The Press Release is also available on the website of the Company i.e. www.aartipharmalabs.com

Please take the same on your records.

Thanking you,

Yours faithfully,
For AARTI PHARMALABS LIMITED

JEEVAN MONDKAR
COMPANY SECRETARY AND LEGAL HEAD
ICSI M. NO. A22565

Encl.: a/a.



We are pleased to inform you that the company has inaugurated phase 1 at the greenfield manufacturing facility located at Atali, District Bharuch, Gujarat. The company has successfully obtained all the necessary permissions and approvals to start the facility. Phase 1 has a total reactor capacity of 440 kL with 63 reactors. It is noteworthy that this greenfield site is spread across 80 acres of land and in future, is scalable up to capacity of 8-10 times that of phase 1.

Commenting on this milestone, **Mr. Rashesh Gogri, Chairman of Aarti Pharmalabs**, said:

Starting the seventh manufacturing site is a significant milestone in the growth trajectory of Aarti Pharmalabs. This site will serve as a growth engine for the CDMO / CMO business and enhance the intermediates capacity. The inauguration of phase 1 is only the beginning of a journey. We envisage to set up additional manufacturing blocks at this site to ultimately advance towards CDMO / CMO revenue goal of Rs. 1000 crores. With state of the art infrastructure, this site will help strengthen our product portfolio and serve innovators and large pharmaceutical companies.

The inauguration event witnessed the presence of our Chairman, Managing Directors, the Senior Management team, alongside the dedicated members of the Aarti Pharmalabs team. This new venture emphasizes a commitment towards company growth and capability development to cater to specialized pharmaceutical needs.

About Aarti Pharmalabs Limited

Aarti Pharmalabs Limited (NSE: AARTIPHARM | BSE: 543748) is a prominent Indian pharmaceutical and nutraceutical manufacturer with a global presence. It focuses on innovation, sustainability, and is one of the leaders in the pharmaceutical and nutraceutical domain. The company specializes in offering comprehensive CDMO/CMO services for small molecule drug substances, catering to clinical and commercial phase projects for innovator pharma companies, with dedicated facilities for HPAPIs, corticosteroids, cytotoxic, and oncology products. It also offers generic APIs and Intermediates, and is globally amongst top producers of Xanthine derivatives.

Plant Location: R.S.No 39 to 49, PCPIR Notified Industrial Area, Village Atali, Dist Bharuch, Gujarat 392130